HBM contact: Dr Chandra P. Leo
Company status: private
Arrakis is pioneering the discovery of small-molecule medicines that
directly bind to and modify the biological function of RNA to treat disease.
This new class of medicines, RNA-targeted small molecules (rSMs), can unlock
the therapeutic potential of deeply researched, valuable targets that are not
accessible at the level of their expressed, undruggable protein.